Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 ...

A Phase 3 clinical trial investigating Elevidys (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular ...

A Pfizer result is unsettling the gene therapy push for Duchenne muscular dystrophy: The boys didn't improve even though a ...

Sidra Medicine s Genetic and Genomic Medicine clinic is providing life altering gene therapy for rare genetic disorders. In a ...

Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. | Capricor ...

Capricor Therapeutics started its rolling submission seeking FDA approval of its DMD therapy deramiocel for heart muscle ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has once again snubbed Translarna ...

SAVANNAH, Ga. -- Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, ...

CHMP upheld earlier opinions that Translarna is not of significant benefit to DMD due to nonsense mutations; European ...

研究结果为DMD发病机制，特别是疾病早期的分子和细胞变化提供了新的见解。揭示了免疫、纤维化以及肌肉干细胞在DMD早期的动态变化，为早期干预 ...

trial for its Duchenne muscular dystrophy (DMD) cell therapy, deramiocel. Last week, the company started rolling submissions for a biologics license application (BLA) for deramiocel as a treatment ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.